New Drugs 2010-2011- Pharmacist

  Price  

  Credits  2

This product is currently out of stock and unavailable.


Format
In 2010, the FDA approved 21 new molecular entities (NMEs) down from 25 in 2009. A few of these are potential blockbusters including fingolimod (GilenyaTM), the first oral multiple sclerosis drug, and dabigatran (Pradaxa®), the first warfarin alternative. In addition to these NMEs, this issue reviews several more that are likely to be of interest to community-based practitioners including dalfampridine (AmpyraTM), denosumab (ProliaTM, XgevaTM), liraglutide (Victoza®), ulipristal (Ella®), and a new combination dextromethorphan /quinidine (NuedextaTM). Each review summarizes the drug’s role in therapy, usual dose, precautions and drug interactions. Useful and practical patient counseling points are highlighted separately for easy access. Combination products are becoming more commonplace, especially in the chronic disease arena (e.g., high blood pressure and diabetes). A brief summary of the advantages and potential disadvantages of fixed combinations is provided in this issue. Practical tables outline other NMEs, new combination products and significant new dosage forms you are likely to encounter in practice.

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 0428-0000-11-103-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.